| Literature DB >> 34259561 |
Ellen T Kiser1, Mark A Wacker2, Upasna Gaur Dixit2, Hemali Batra-Sharma3, Yani Chen2,4, Mary E Wilson1,2,3,4.
Abstract
Visceral leishmaniasis is a potentially fatal disease caused by the protozoon Leishmania donovani or L. infantum (Li). Although previous studies revealed that high lipid intake reduces parasite burdens in Leishmania donovani-infected mice, the specific contributions of dietary lipids to Li-associated pathogenesis are not known. To address this, we evaluated parasite growth, liver pathology, and transcriptomic signatures in Li-infected BALB/c mice fed either a control, high-fat, high-cholesterol, or high-fat-high-cholesterol diet. Using quantitative PCR (qPCR), we observed significantly reduced liver parasite burdens in mice fed the high-fat-high-cholesterol diet compared to mice fed the control diet. In contrast to the liver, parasite expansion occurred earlier in the spleens of mice fed the experimental diets. Histological examination revealed an intense inflammatory cell infiltrate in livers predominantly composed of neutrophils caused by the high-fat-high-cholesterol diet specifically. After 8 weeks of infection (12 weeks of diet), Illumina microarrays revealed significantly increased expression of transcripts belonging to immune- and angiogenesis-related pathways in livers of both uninfected and Li-infected mice fed the high-fat-high-cholesterol diet. These data suggest that increased fat and cholesterol intake prior to Li infection leads to a hepatic inflammatory environment and thus reduces the parasite burden in the liver. Defining inflammatory signatures as well as pathology in the liver may reveal opportunities to modify the therapeutic approach to Li infection. IMPORTANCE Leishmaniasis is a spectrum of diseases caused by Leishmania species protozoa that is most common in warm climates, coinciding with impoverished regions. Visceral leishmaniasis is a potentially fatal disease in which parasites infect reticuloendothelial organs and cause progressive wasting and immunocompromise. The distribution and demographics of visceral leishmaniasis have changed over recent years, coinciding with modernizing societies and the increased availability of Western diets rich in lipid content. We report here that increased dietary fat and cholesterol intake affected disease pathogenesis by increasing inflammation and reducing localized parasite burdens in the liver. These diet-induced changes in disease pathogenesis might explain in part the changing epidemiology of visceral leishmaniasis. A relationship between diet and inflammatory responses may occur in leishmaniasis and other microbial or immune-mediated diseases, possibly revealing opportunities to modify the therapeutic approach to microbial infections.Entities:
Keywords: dietary lipids; inflammation; leishmaniasis; neglected tropical diseases; transcriptome
Mesh:
Substances:
Year: 2021 PMID: 34259561 PMCID: PMC8386445 DOI: 10.1128/mSphere.00423-21
Source DB: PubMed Journal: mSphere ISSN: 2379-5042 Impact factor: 4.389
Macronutrients and cholesterol in experimental diets
| Diet | % content (% kcal) | |||
|---|---|---|---|---|
| Control | High fat | High cholesterol | High fat-high | |
| Protein | 18.6 | 17.3 (15.2) | 17.8 (22.9) | 17.3 (15.5) |
| Carbohydrates | 44.2 | 48.5 (42.7) | 47.0 (60.5) | 46.9 (41.9) |
| Fat | 6.2 | 21.2 (42.0) | 5.7 (16.6) | 21.2 (42.6) |
| Cholesterol | 0.2 | 2 | 1.3 | |
Diets were obtained from Envigo (Indianapolis, IN). The percentages (by weight) of each macronutrient and cholesterol are listed. The percentages of kilocalories for macronutrients are also listed in parentheses for the experimental diets.
FIG 1(A) Diet impacts organ weight. Organs were collected from Li-infected and uninfected BALB/c mice after 8 weeks of the experimental diets. The liver and spleen were weighed (n = 2 replicates for uninfected mice and 5 replicates for infected mice) (means and standard deviations) (**, P < 0.005; ****, P < 0.0001 [by two-way ANOVA with a Sidak posttest comparing uninfected and infected mice fed the experimental diets to uninfected mice fed the control {Con} diet]). HF, high fat; HF-HC, high fat-high cholesterol. (B) Diet changed infection kinetics. At 4 and 8 weeks postinfection, BALB/c mice were euthanized, and qPCR was performed using primers targeting Li kinetoplast DNA. For each mouse, two technical replicates were analyzed, and the mean was determined before calculating the number of parasites per liver and spleen using the comparative C method. The mean numbers of parasites per liver and spleen were then pooled, and outliers were removed before calculating the mean for each experimental group (n = ∼15 [3 independent experiments with n = ∼5 for each]; ROUT identified and removed ≤4 outliers per group) (means and standard errors of the means [SEM]) (*, P < 0.05 [by one-way ANOVA with a Dunnett posttest comparing experimental diets to the control diet]). (C) IVIS images reflect qPCR at 4 weeks. BALB/c mice fed experimental diets were infected with Li transfected to express the firefly luciferase gene, and infection status was monitored by IVIS. Parasite localization was imaged 10 and 15 min after luciferin administration. Images were taken at 4 weeks postinfection. The key indicates the number of pixels.
FIG 2Diet impacts liver cellular composition and lipid content. (A) Organs were collected from uninfected BALB/c mice after 4 weeks of the experimental diets. Slides were prepared, and cells were counted by light microscopy. The images are representative of multiple slides. The numbers of total lymphocytes and polymorphonuclear leukocytes (PMNs) were counted in 10 high-power (magnification, ×1,000) fields per uninfected mouse, and the sum for each mouse was calculated before calculating a mean for each group (n = 5) (means and standard deviations) (***, P < 0.0005; ****, P < 0.0001 [by one-way ANOVA with a Dunnett posttest comparing uninfected mice fed experimental diets to uninfected mice fed the control {Con} diet]). HC, high cholesterol; HF, high fat; HF-HC, high fat-high cholesterol. (B) Tissues were collected from uninfected mice after 4 weeks of the experimental diets, and Oil-Red-O staining was performed. Images are representative of multiple slides.
FIG 3Transcript abundance in uninfected mice fed experimental diets. RNA extracted from the livers of uninfected and Li-infected mice fed various diets was examined using an Illumina MouseRef-8 V2.0 microarray. The resulting data were analyzed using Illumina Genome Studio and Partek. In Partek, one-way ANOVA was used to determine the differential abundances of transcripts. The transcript abundances in uninfected and Li-infected mice fed the experimental diets (high fat [HF], high cholesterol [HC], and high fat-high cholesterol [HF-HC]) were compared to those in uninfected and Li-infected mice fed the control (Con) diet, respectively. The fold change of each transcript was calculated in Partek (n = 3 for each diet). The P and q values were also calculated as a function of one-way ANOVA performed in Partek. All transcripts in the reference genome are depicted via a volcano plot, with significantly increased transcripts in green, significantly decreased transcripts in pink, and transcripts that did not significantly change in gray. A q value of <0.10 was considered significant (n = 3 mice for each diet).
Pathway overrepresentation analysis of uninfected mice fed experimental diets
| Diet | PANTHER pathway (PANTHER ID no.) | No. of transcripts | FDR | ||
|---|---|---|---|---|---|
| Observed | Expected | ||||
| High fat (decreased) | p53 pathway (P00059) | 12 | 2.96 | 9.87E−05 | 8.19E−03 |
| Parkinson disease (P00049) | 11 | 3.23 | 7.37E−04 | 3.06E−02 | |
| FGF signaling pathway (P00021) | 13 | 4.08 | 4.52E−04 | 2.50E−02 | |
| Unclassified (unclassified) | 627 | 668.74 | 1.26E−05 | 2.09E−03 | |
| High fat (increased) | No significant results | ||||
| High cholesterol (decreased) | Unclassified (unclassified) | 859 | 914.32 | 8.17E−07 | 1.36E−04 |
| High cholesterol (increased) | Circadian clock system (P00015) | 5 | 0.44 | 3.11E−04 | 2.58E−02 |
| Inflammation mediated by chemokine and cytokine signaling pathway (P00031) | 28 | 12.65 | 3.13E−04 | 1.73E−02 | |
| Unclassified (unclassified) | 912 | 964.68 | 4.03E−06 | 6.68E−04 | |
| High fat-high cholesterol (decreased) | Ubiquitin proteasome pathway (P00060) | 14 | 3.71 | 7.55E−05 | 1.25E−02 |
| Unclassified (unclassified) | 1,061 | 1,105.14 | 2.66E−04 | 2.21E−02 | |
| High fat-high cholesterol (increased) | Toll receptor signaling pathway (P00054) | 20 | 3.89 | 5.29E−08 | 2.19E−06 |
| T cell activation (P00053) | 28 | 6.36 | 2.21E−09 | 1.83E−07 | |
| B cell activation (P00010) | 20 | 4.95 | 1.29E−06 | 3.58E−05 | |
| Apoptosis signaling pathway (P00006) | 28 | 8.34 | 2.90E−07 | 9.63E−06 | |
| VEGF signaling pathway (P00056) | 15 | 4.88 | 3.63E−04 | 4.63E−03 | |
| Ras pathway (P04393) | 15 | 4.95 | 4.14E−04 | 4.91E−03 | |
| Interleukin signaling pathway (P00036) | 18 | 6.22 | 1.90E−04 | 2.63E−03 | |
| Inflammation mediated by chemokine and cytokine signaling pathway (P00031) | 50 | 18.24 | 3.85E−09 | 2.13E−07 | |
| Cytoskeletal regulation by Rho GTPase (P00016) | 15 | 5.58 | 1.23E−03 | 1.36E−02 | |
| Angiogenesis (P00005) | 31 | 11.95 | 9.06E−06 | 2.15E−04 | |
| PDGF signaling pathway (P00047) | 26 | 10.11 | 5.66E−05 | 9.40E−04 | |
| EGF receptor signaling pathway (P00018) | 24 | 9.61 | 1.53E−04 | 2.32E−03 | |
| CCKR signaling map (P06959) | 28 | 11.24 | 4.34E−05 | 8.00E−04 | |
| Integrin signaling pathway (P00034) | 33 | 13.43 | 1.51E−05 | 3.12E−04 | |
| p53 pathway (P00059) | 15 | 6.15 | 3.74E−03 | 3.88E−02 | |
| Unclassified (unclassified) | 1,264 | 1,390.48 | 1.34E−18 | 2.22E−16 | |
Observed, number of transcripts in the data that represent a given pathway; expected, number of transcripts that are expected to represent a given pathway for a data list the size of the list entered; FGF, fibroblast growth factor; VEGF, vascular endothelial growth factor; CCKR, cholecystokinin receptor.
Pathway overrepresentation analysis of infected mice fed experimental diets
| Diet | PANTHER pathway (PANTHER ID no.) | No. of transcripts | FDR | ||
|---|---|---|---|---|---|
| Observed | Expected | ||||
| High fat (decreased) | No significant results | ||||
| High fat (increased) | VEGF signaling pathway (P00056) | 12 | 2.9 | 9.43E−05 | 7.83E−03 |
| Toll receptor signaling pathway (P00054) | 9 | 2.31 | 1.02E−03 | 4.25E−02 | |
| T cell activation (P00053) | 12 | 3.78 | 8.33E−04 | 4.61E−02 | |
| Unclassified (unclassified) | 758 | 826.87 | 1.91E−10 | 3.16E−08 | |
| High cholesterol (decreased) | Blood coagulation (P00011) | 8 | 5.97 | 1.24E−04 | 2.05E−02 |
| High cholesterol (increased) | No significant results | ||||
| High fat-high cholesterol (decreased) | Pyrimidine metabolism (P02771) | 6 | 0.62 | 1.72E−04 | 1.43E−02 |
| Blood coagulation (P00011) | 18 | 2.88 | 1.45E−08 | 2.41E−06 | |
| Unclassified (unclassified) | 1,066 | 1,111.32 | 1.94E−04 | 1.07E−02 | |
| High fat-high cholesterol (increased) | Toll receptor signaling pathway (P00054) | 20 | 3.77 | 3.24E−08 | 8.97E−07 |
| T cell activation (P00053) | 28 | 6.16 | 1.14E−09 | 6.33E−08 | |
| VEGF signaling pathway (P00056) | 21 | 4.73 | 1.81E−07 | 3.77E−06 | |
| Ras pathway (P04393) | 21 | 4.79 | 2.22E−07 | 4.09E−06 | |
| B cell activation (P00010) | 20 | 4.79 | 8.16E−07 | 1.13E−05 | |
| Cytoskeletal regulation by Rho GTPase (P00016) | 21 | 5.41 | 1.18E−06 | 1.50E−05 | |
| Axon guidance mediated by semaphorins (P00007) | 6 | 1.58 | 9.11E−03 | 5.04E−02 | |
| Apoptosis signaling pathway (P00006) | 30 | 8.08 | 1.55E−08 | 5.15E−07 | |
| Inflammation mediated by chemokine and cytokine signaling pathway (P00031) | 63 | 17.67 | 1.13E−15 | 9.37E−14 | |
| Axon guidance mediated by netrin (P00009) | 8 | 2.4 | 5.42E−03 | 3.46E−02 | |
| EGF receptor signaling pathway (P00018) | 31 | 9.32 | 7.66E−08 | 1.82E−06 | |
| CCKR signaling map (P06959) | 36 | 10.89 | 8.18E−09 | 3.39E−07 | |
| Interferon gamma signaling pathway (P00035) | 7 | 2.12 | 9.59E−03 | 4.98E−02 | |
| FGF signaling pathway (P00021) | 27 | 8.22 | 6.46E−07 | 1.07E−05 | |
| Histamine H1 receptor-mediated signaling pathway (P04385) | 10 | 3.08 | 2.35E−03 | 1.70E−02 | |
| Interleukin signaling pathway (P00036) | 19 | 6.03 | 4.61E−05 | 4.50E−04 | |
| Angiotensin II-stimulated signaling through G proteins and beta-arrestin (P05911) | 8 | 2.67 | 9.38E−03 | 5.02E−02 | |
| 5HT1-type receptor-mediated signaling pathway (P04373) | 9 | 3.01 | 6.11E−03 | 3.63E−02 | |
| Oxytocin receptor-mediated signaling pathway (P04391) | 12 | 4.04 | 1.74E−03 | 1.37E−02 | |
| Parkinson disease (P00049) | 19 | 6.51 | 1.12E−04 | 1.03E−03 | |
| p53 pathway (P00059) | 17 | 5.96 | 3.20E−04 | 2.79E−03 | |
| Thyrotropin-releasing hormone receptor signaling pathway (P04394) | 12 | 4.25 | 2.49E−03 | 1.66E−02 | |
| PI3 kinase pathway (P00048) | 10 | 3.56 | 5.76E−03 | 3.54E−02 | |
| 5HT2-type receptor-mediated signaling pathway (P04374) | 13 | 4.66 | 1.85E−03 | 1.40E−02 | |
| Angiogenesis (P00005) | 32 | 11.58 | 1.72E−06 | 1.90E−05 | |
| PDGF signaling pathway (P00047) | 27 | 9.79 | 1.13E−05 | 1.17E−04 | |
| Integrin signaling pathway (P00034) | 35 | 13.01 | 1.31E−06 | 1.56E−05 | |
| Endothelin signaling pathway (P00019) | 15 | 5.62 | 1.27E−03 | 1.05E−02 | |
| Gonadotropin-releasing hormone receptor pathway (P06664) | 41 | 16.16 | 6.73E−07 | 1.02E−05 | |
| Huntington disease (P00029) | 22 | 10.27 | 2.42E−03 | 1.68E−02 | |
| Heterotrimeric G-protein-signaling pathway–Gq alpha- and Go alpha-mediated pathway (P00027) | 17 | 8.29 | 8.32E−03 | 4.76E−02 | |
| Unclassified (unclassified) | 1,187 | 1,347.19 | 1.24E−28 | 2.06E−26 | |
Observed, number of transcripts in the data that represent a given pathway; expected, number of transcripts that are expected to represent a given pathway for a data list of the size of the list entered; PI3, phosphatidylinositol 3.
Pathway also overrepresented in uninfected mice fed the same diet.
FIG 4Pathway analyses of increased transcripts. Transcripts found to be significantly (P < 0.05) increased (A) or decreased (B) via one-way ANOVA when mice fed the experimental diets were compared to mice fed a control diet were analyzed using functional classification tests via the PANTHER classification system. The PANTHER pathway identification number (in parentheses) is included with the name of the pathway. For each diet, the percentage of significantly changed transcripts that represent a given pathway was graphed (the key depicts 0% to 1.5%). Pathways for which more than 1.5% of transcripts were representative are in pink. Fewer than 4.5% of transcripts were assigned to any given pathway. Only pathways that the statistical overrepresentation tests found to be significantly overrepresented in at least one of the experimental diets fed to either infected or uninfected mice are included (n = 3 uninfected and infected mice for each experimental diet). HC, high cholesterol; HF, high fat; HF-HC, high fat-high cholesterol.
The most significant pathways and their transcripts with differential abundances in infected mice
| Diet | PANTHER pathway (PANTHER ID no.) | FDR | Transcripts |
|---|---|---|---|
| High fat (increased) | VEGF signaling pathway (P00056) | 7.83E−03 |
|
| Toll receptor signaling pathway (P00054) | 4.25E−02 |
| |
| T cell activation (P00053) | 4.61E−02 |
| |
| High cholesterol (decreased) | Blood coagulation (P00011) | 2.05E−02 |
|
| High fat-high cholesterol (decreased) | Blood coagulation (P00011) | 2.41E−06 |
|
| Pyrimidine metabolism (P02771) | 1.43E−02 |
| |
| High fat-high cholesterol (increased) | Inflammation mediated by chemokine and cytokine signaling pathway (P00031) | 9.37E−14 |
|
| T cell activation (P00053) | 6.33E−08 |
| |
| CCKR signaling map (P06959) | 3.39E−07 |
| |
| Apoptosis signaling pathway (P00006) | 5.15E−07 |
| |
| Toll receptor signaling pathway (P00054) | 8.97E−07 |
| |
| EGF receptor signaling pathway (P00018) | 1.82E−06 |
| |
| VEGF signaling pathway (P00056) | 3.77E−06 |
| |
| Ras pathway (P04393) | 4.09E−06 |
| |
| Gonadotropin-releasing hormone receptor pathway (P06664) | 1.02E−05 |
| |
| FGF signaling pathway (P00021) | 1.07E−05 |
| |
For increased and decreased transcripts in each diet, only the 10 most significantly overrepresented pathways are included.
Pathway also overrepresented in uninfected mice fed the same diet.
FIG 5qPCR validation of transcript expression in infected mice. Using SYBR green qPCR, the abundance of transcripts was validated to further examine the changes in infection severity due to diet. For each mouse, the mean of 3 replicate C values for each transcript of interest was calculated. Using the comparative C method, the fold change of each transcript was determined by comparing infected mice fed one of the four diets (control [Con], high cholesterol [HC], high fat [HF], and high fat-high cholesterol [HF-HC]) to uninfected mice fed the control diet. gapdh was used as the internal control. (n = 3) (means and SEM) (*, P < 0.05; **, P < 0.005; ***, P < 0.0005 [by one-way ANOVA with a Dunnett posttest comparing infected mice fed the experimental diets to infected mice fed the control diet]).
The most significant pathways and their transcripts with differential abundances in uninfected mice
| Diet | PANTHER pathway (PANTHER ID no.) | FDR | Transcripts |
|---|---|---|---|
| High fat (decreased) | p53 pathway (P00059) | 8.19E−03 |
|
| FGF signaling pathway (P00021) | 2.50E−02 |
| |
| Parkinson disease (P00049) | 3.06E−02 |
| |
| High cholesterol (increased) | Inflammation mediated by chemokine and cytokine signaling pathway (P00031) | 1.73E−02 |
|
| Circadian clock system (P00015) | 2.58E−02 |
| |
| High fat-high cholesterol (decreased) | Ubiquitin proteasome pathway (P00060) | 1.25E−02 |
|
| High fat-high cholesterol (increased) | T cell activation (P00053) | 1.83E−07 |
|
| Inflammation mediated by chemokine and cytokine signaling pathway (P00031) | 2.13E−07 |
| |
| Toll receptor signaling pathway (P00054) | 2.19E−06 |
| |
| Apoptosis signaling pathway (P00006) | 9.63E−06 |
| |
| B cell activation (P00010) | 3.58E−05 |
| |
| Angiogenesis (P00005) | 2.15E−04 |
| |
| Integrin signaling pathway (P00034) | 3.12E−04 |
| |
| CCKR signaling map (P06959) | 8.00E−04 |
| |
| PDGF signaling pathway (P00047) | 9.40E−04 |
| |
| EGF receptor signaling pathway (P00018) | 2.32E−03 |
| |
For increased and decreased transcripts in each diet, only the 10 most significantly overrepresented pathways are included.